PRESS RELEASE

New long-term and real-world data on BRIUMVI® (ublituximab) presented at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026

New scientific data in relapsing forms of multiple sclerosis (RMS) were presented across a series of poster presentations led by MS experts

Data presented at MSToronto2026 reinforce the growing body of evidence supporting the therapy, with more than 30,000 patients treated worldwide[1]

Barcelona, Spain, and Düsseldorf, Germany – 23 October 2026 – **Neuraxpharm Group (Neuraxpharm)**, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announced the presentation of new scientific data on BRIUMVI® (ublituximab) at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, held October 21-23, 2026, in Toronto, Canada. Presented in collaboration with partner TG Therapeutics, the data add to the growing body of evidence supporting the use of the therapy in patients with relapsing forms of multiple sclerosis (RMS).

As the world's largest scientific meeting dedicated to multiple sclerosis (MS), MSToronto2026 brought together healthcare professionals, researchers and patient advocates from around the globe to discuss the latest advances in MS research and care.

Across a series of poster presentations, investigators shared new evidence on the long-term efficacy and safety profile of ublituximab, patient-reported outcomes from routine clinical practice and data exploring alternative infusion approaches. Together, these findings further expand the growing body of evidence supporting the use of this therapy in RMS and may help inform clinical decision-making in everyday practice. Key data presented at the meeting included:

Seven-year safety and efficacy outcomes for ublituximab treatment in Relapsing MS[2] - New long-term follow-up data demonstrated that early initiation of treatment and continued treatment over a period of seven years provided patients with sustained clinical benefit. Safety and efficacy outcomes remained consistent through year seven, further supporting the long-term use of high-efficacy disease-modifying therapies in RMS. The treatment continued to provide significant control of disease activity and improvements in disability outcomes while maintaining a consistent safety profile[2].

BRILL study - Results from the ongoing BRILL real-world study showed high levels of treatment satisfaction and health-related quality of life after almost one year of infusion treatment, particularly regarding side effects, convenience and overall satisfaction. These outcomes were reflected in a high treatment confirmation rate[3].

The findings also demonstrated that infusion-related reactions (IRRs) occurred most frequently during the first infusion and declined steadily with subsequent doses, consistent with the established profile of anti-CD20 therapies. Effectiveness outcomes were aligned with the product profile, with the proportion of patients experiencing an MS relapse decreasing by 93% during the first 48 weeks after initiating treatment compared with the preceding 12 months[3].

ENABLE study - Updated analyses from the ENABLE programme provided additional real-world evidence supporting the safety and efficacy outcomes observed in the pivotal clinical trials. The largest category of patients starting the therapy in ENABLE is treatment-naïve, followed by patients transitioning from prior B-cell therapies. Updated data includes additional enrolled participants, now with a sample of 1076 MS patients[4].

ENHANCE study - Data from the randomised portion of the ENHANCE clinical programme provided a robust, head-to-head comparison of a single 600 mg infusion at day 1 with the currently approved regimen of 150 mg at day 1 and 450 mg at day 15. The findings suggest comparable exposure with a favourable benefit-risk profile, potentially providing an additional treatment option for patients and healthcare professionals[5].

Alongside the scientific programme, Neuraxpharm and TG Therapeutics maintained a strong presence at MSToronto2026 through a dedicated scientific booth and Business Suite, providing opportunities for engagement and scientific exchange with healthcare professionals from across the global MS community.

Neuraxpharm also hosted the Balance Board activity, supporting a donation to the European Multiple Sclerosis Platform (EMSP) and reflecting our ongoing commitment to supporting people affected by multiple sclerosis.

MSToronto2026 welcomed approximately 10,000 participants, with a high level of engagement from healthcare professionals at the Neuraxpharm and TG Therapeutics booth and scientific sessions throughout the event.

In addition to the data presented at MSToronto2026, a new analysis entitled *"Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison"* was recently published in *Multiple Sclerosis and Related Disorders*[6]. These findings suggest directionally favourable long-term outcomes with ublituximab compared with the other two comparators. These findings should be interpreted carefully within the assumptions and inherent limitations of the unanchored MAIC approach[6].

For further information please contact:

Optimum Strategic Communications
Nick Bastin / Charlotte Hepburne-Scott / Nellie Stephens / Ben Cowe
Tel: +44 (0)203 882 9621
Neuraxpharm@optimumcomms.com

About ublituximab 150 mg/6 mL Injection for IV

In the EU, it is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Ublituximab is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS.

Link to EMA-SmPC.

About the Neuraxpharm Group

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, including both psychiatric and neurological conditions, with a unique understanding of the CNS market.

Neuraxpharm is constantly innovating new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions. The company has more than 1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, in Australia and globally via partners in more than 50 countries.

Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals in Spain.

For more information, please visit https://www.neuraxpharm.com/

References

[1] TG Therapeutics Second Quarter Conference Call, originally broadcast on Monday, 3 August 2026 at 8:30 a.m. EDT

[2] Cree B. et al. Seven-Year Safety and Efficacy Outcomes for Ublituximab Treatment in Relapsing MS. P0367 Presented at the 10th Joint ACTRIMS-ECTRIMS Meeting | 21-23 October 2026 | Toronto, Canada

[3] Salmen A. et al. Real-world Data of Ublituximab in Relapsing Forms of Multiple Sclerosis: 48-Week Interim Results From the Non-interventional BRILL Study. EP2641 Presented at the 10th Joint ACTRIMS-ECTRIMS Meeting | 21-23 October 2026 | Toronto, Canada

[4] Hersh C. et al. Real-world Safety and Efficacy Outcomes in Relapsing Multiple Sclerosis Patients Initiating Ublituximab in the Phase 4 Observational Study ENABLE. P0403 Presented at the 10th Joint ACTRIMS-ECTRIMS Meeting | 21-23 October 2026 | Toronto, Canada

[5] Robertson D. et al. Randomized, Double-Blind Evaluation of a Consolidated Ublituximab Initial Dosing Regimen Versus Conventional Ublituximab Regimen. P1419 Presented at the 10th Joint ACTRIMS-ECTRIMS Meeting | 21-23 October 2026 | Toronto, Canada

[6] Gold R. et al. Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison. *Multiple Sclerosis and Related Disorders*. 2026;115:107953.